Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Erna Milunka Kojic, Aadia I. Rana & Susan Cu-Uvin. (2016) Human papillomavirus vaccination in HIV-infected women: need for increased coverage. Expert Review of Vaccines 15:1, pages 105-117.
Read now
Read now
Articles from other publishers (11)
Juan Li, Li-Wei Shi, Bang-Wei Yu, Li-Rong Huang, Ling-Yun Zhou, Li Shi, Zhi-Wei Jiang, Jie-Lai Xia, Xuan-Yi Wang, Rong-Cheng Li, Lin Yuan, Yan-Ping Li & Chang-Gui Li. (2023) Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9–45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial. Vaccine 41:19, pages 3141-3149.
Crossref
Crossref
Joel M. Palefsky, Selvamuthu Poongulali, Shelly Lensing, Jeannette Lee, Maria Da Costa, Aung Chein, Faith Beulah, K. G. Murugavel & Nagalingeswaran Kumarasamy. (2021) AIDS Malignancy Consortium 054: Safety and Immunogenicity of the Quadrivalent Vaccine in Indian Women Living With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes 87:2, pages 875-881.
Crossref
Crossref
Shi Jin, Dong-Dong Zheng, Bo Sun, Xianghui Yu, Xiao Zha, Yongjiang Liu, Shuming Wu & Yuqing Wu. (2016) Controlled Hybrid-Assembly of HPV16/18 L1 Bi VLPs in Vitro. ACS Applied Materials & Interfaces 8:50, pages 34244-34251.
Crossref
Crossref
Jianhui Nie, Weijin Huang, Xueling Wu & Youchun Wang. (2014) Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons. Journal of Medical Virology 86:9, pages 1542-1555.
Crossref
Crossref
Joshua W. Wang, Subhashini Jagu, Chenguang Wang, Henry C. Kitchener, Sai Daayana, Peter L. Stern, Susana Pang, Patricia M. Day, Warner K. Huh & Richard B. S. Roden. (2014) Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions. PLoS ONE 9:7, pages e101576.
Crossref
Crossref
E. M. Kojic, M. Kang, M. S. Cespedes, T. Umbleja, C. Godfrey, R. T. Allen, C. Firnhaber, B. Grinsztejn, J. M. Palefsky, J. Y. Webster-Cyriaque, A. Saah, J. A. Aberg & S. Cu-Uvin. (2014) Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Women. Clinical Infectious Diseases 59:1, pages 127-135.
Crossref
Crossref
Paul L. McCormack. (2014) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): A Review of Its Use in the Prevention of Premalignant Anogenital Lesions, Cervical and Anal Cancers, and Genital Warts. Drugs 74:11, pages 1253-1283.
Crossref
Crossref
Mel Krajden, Darrel Cook, Amanda Yu, Ron Chow, Qiang Su, Wendy Mei, Shelly McNeil, Deborah Money, Marc Dionne, Joel Palefsky, Karuna Karunakaran, Tobias Kollmann, Gina Ogilvie, Martin Petric & Simon Dobson. (2014) Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine 32:5, pages 624-630.
Crossref
Crossref
Qinjian Zhao, Shaowei Li, Hai Yu, Ningshao Xia & Yorgo Modis. (2013) Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends in Biotechnology 31:11, pages 654-663.
Crossref
Crossref
Matti Lehtinen & Joakim Dillner. (2013) Clinical trials of human papillomavirus vaccines and beyond. Nature Reviews Clinical Oncology 10:7, pages 400-410.
Crossref
Crossref
Hiroyuki Yoshikawa, Keiko Ebihara, Yoshiyuki Tanaka & Kiichiro Noda. (2013)
Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (
GARDASIL
) in
J
apanese women aged 18–26 years
. Cancer Science 104:4, pages 465-472.
Crossref
Crossref